Efficacy of venetoclax plus anti‐CD38 monoclonal antibody‐containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody

威尼斯人 养生 医学 多发性骨髓瘤 单克隆抗体 抗体 CD38 内科学 肿瘤科 地塞米松 达拉图穆马 硼替佐米 胃肠病学 免疫学 白血病 生物 慢性淋巴细胞白血病 川地34 遗传学 干细胞
作者
Bernard Regidor,Dilawer Siddiqi,Bethany Marie Beatty,Marissa-Skye Goldwater,Scott Jew,Sean Bujarski,Regina A. Swift,Susanna Kim,James R. Berenson
出处
期刊:European Journal of Haematology [Wiley]
卷期号:110 (2): 222-223
标识
DOI:10.1111/ejh.13896
摘要

This study identifies a potential effective therapeutic approach and treatment option for RRMM patients with t(11;14) with prior exposure to anti-CD38 medications and should lead to more extensive evaluation of this combination therapy regardless of time from prior exposure to a CD38 antibody as part of another treatment regimen. Anti-CD38 mAbs are standard treatment options for RRMM patients.1-3 The relationship between the time since treatment with a prior anti-CD38 mAb regimen and the efficacy of another therapy containing these antibodies is limited and has not been reported for a combination containing venetoclax. In a study investigating isatuximab monotherapy for daratumumab refractory MM patients, the disease control rate was greater among those with a time from their last daratumumab to isatuximab of >6 months versus those <3 months.4 Venetoclax, a BCL-2 inhibitor, has shown efficacy for RRMM patients with t(11;14) when combined with bortezomib, dexamethasone, and daratumumab.5-8 This study investigated the relationship between the time since the last anti-CD38 mAb treatment and the efficacy of a venetoclax and anti-CD38 mAb-containing regimen among RRMM patients with t(11;14). All MM patients with t(11;14) who received a venetoclax and an anti-CD38 mAb-containing regimen were identified between January 2017 and April 2022. Those treated with this combination and who had received at least one prior anti-CD38 mAb regimen were included. Patients were excluded if the venetoclax plus anti-CD38 mAb-containing treatment was initiated at another clinic. Among the 11 patients, all received venetoclax with daratumumab, bortezomib, and dexamethasone except for one patient who received this combination without bortezomib. Overall response rate (ORR) and clinical benefit rate (CBR) were 64% (7/11) and 73% (8/11), respectively (Table 1). Among the eight responders (i.e., ≥CBR), the median time between the last anti-CD38 mAb treatment and the venetoclax and anti-CD38 mAb-containing regimen was 25 days (range: 5–239 days). Seven responders initiated the venetoclax plus anti-CD38 treatment <120 days after prior anti-CD38 mAb exposure (Table 1). The only patient who achieved a very good partial response started venetoclax 5 days after failing the prior anti-CD38 treatment (Table 1). Thus, venetoclax plus anti-CD38 mAb-containing regimens are effective for RRMM patients with t(11;14) regardless of the time that elapsed from their previous anti-CD38 mAb exposure as part of another regimen. Compared to our group's prior study investigating multiple exposures to anti-CD38 mAbs, the venetoclax plus anti-CD38 mAb combination in this subpopulation with t(11;14) had a greater ORR (64% vs. 40.8%) and CBR (73% vs. 42.9%) than what we previously reported among all RRMM patients treated with another anti-CD38 mAb-containing combination.9 Furthermore, compared to reports of greater efficacy among patients receiving anti-CD38 mAb regimens after a 6-month washout period from this antibody treatment, all except one responding patient in this study were treated <120 days from prior anti-CD38 mAb treatment.4 This suggests that a 6-month time without exposure to an anti-CD38 mAb is unnecessary for RRMM patients with t(11;14) receiving venetoclax and anti-CD38 mAb-containing therapy. It is possible that venetoclax alone or in combination with bortezomib may have produced the clinical activity as has been previously reported.10, 11 We believe this study warrants further investigation of the combination of venetoclax with an anti-CD38 mAb for RRMM patients with t(11;14) without requiring a specific time to elapse from prior anti-CD38 mAb treatment. James R. Berenson designed the study. Regina Swift collected specimens for analysis. Bernard Sean Regidor, Dilawer Siddiqi, Bethany Marie Beatty, and Marissa-Skye Goldwater generated the data. Bernard Sean Regidor, Dilawer Siddiqi, Bethany Marie Beatty, Scott Jew, Sean Bujarski, Marissa-Skye Goldwater, Susanna Kim, and James R. Berenson organized the data. Bernard Sean Regidor, Scott Jew, Marissa-Skye Goldwater, and Sean Bujarski analyzed the data. Bernard Sean Regidor, Dilawer Siddiqi, Bethany Marie Beatty, Marissa-Skye Goldwater, Susanna Kim, and James R. Berenson wrote the manuscript. The authors thank the patients at Berenson Cancer Center for their contributions to the study and all healthcare professional staff involved in collecting clinical specimens. James R. Berenson receives speaker fees from Janssen and has been on advisory boards with Janssen and Abbvie. All other authors declare that they have no conflict of interest. There was no other funding for this study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
向往完成签到,获得积分10
1秒前
CodeCraft应助碎冰采纳,获得10
1秒前
ht完成签到,获得积分20
1秒前
刘刘完成签到,获得积分10
3秒前
GUOXG发布了新的文献求助10
3秒前
cai完成签到,获得积分10
3秒前
求知的周完成签到,获得积分10
4秒前
FashionBoy应助畅快的幻柏采纳,获得10
4秒前
5秒前
少7一点8发布了新的文献求助10
6秒前
淡淡的航空完成签到,获得积分10
8秒前
丘比特应助ruochenzu采纳,获得10
8秒前
9秒前
10秒前
11秒前
ZZICU完成签到,获得积分10
12秒前
依旧发布了新的文献求助30
13秒前
earthai完成签到,获得积分10
16秒前
微生完成签到 ,获得积分10
16秒前
张涛发布了新的文献求助10
17秒前
沙里飞完成签到 ,获得积分10
17秒前
少7一点8完成签到,获得积分20
17秒前
18秒前
豆子完成签到,获得积分10
20秒前
yuefeng完成签到,获得积分10
21秒前
萧水白完成签到,获得积分10
21秒前
雪白起眸完成签到,获得积分20
22秒前
糖果完成签到,获得积分10
22秒前
七里野草完成签到,获得积分10
23秒前
24秒前
25秒前
niu完成签到,获得积分10
25秒前
百香果bxg完成签到 ,获得积分10
25秒前
nicolaslcq完成签到,获得积分10
25秒前
英姑应助着急的盼山采纳,获得10
27秒前
佳雪儿完成签到,获得积分10
27秒前
ttqql应助js110采纳,获得10
28秒前
07先生发布了新的文献求助10
29秒前
畅快代亦完成签到,获得积分10
29秒前
majm完成签到,获得积分10
31秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 820
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
Typology of Conditional Constructions 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3571483
求助须知:如何正确求助?哪些是违规求助? 3142021
关于积分的说明 9445454
捐赠科研通 2843551
什么是DOI,文献DOI怎么找? 1562864
邀请新用户注册赠送积分活动 731380
科研通“疑难数据库(出版商)”最低求助积分说明 718546